BioScrip (NASDAQ:BIOS) was downgraded by research analysts at BidaskClub from a “buy” rating to a “hold” rating in a research report issued to clients and investors on Friday.
A number of other analysts also recently issued reports on the company. SunTrust Banks reissued a “buy” rating and issued a $3.00 target price on shares of BioScrip in a research report on Friday, November 3rd. ValuEngine raised BioScrip from a “strong sell” rating to a “sell” rating in a research report on Thursday, November 9th. Finally, Zacks Investment Research downgraded BioScrip from a “hold” rating to a “sell” rating in a research report on Tuesday, November 7th. Three equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. BioScrip currently has a consensus rating of “Buy” and a consensus target price of $3.63.
BioScrip (BIOS) traded up $0.01 during trading hours on Friday, reaching $2.96. The company’s stock had a trading volume of 613,520 shares, compared to its average volume of 882,641. The company has a quick ratio of 1.60, a current ratio of 1.91 and a debt-to-equity ratio of -6.11. BioScrip has a twelve month low of $1.25 and a twelve month high of $3.39. The stock has a market capitalization of $376.17, a P/E ratio of -4.35 and a beta of 0.27.
In related news, CEO Daniel E. Greenleaf purchased 15,000 shares of the business’s stock in a transaction dated Thursday, November 9th. The stock was purchased at an average cost of $2.03 per share, with a total value of $30,450.00. Following the completion of the acquisition, the chief executive officer now directly owns 31,000 shares of the company’s stock, valued at $62,930. The purchase was disclosed in a document filed with the SEC, which is accessible through this hyperlink. 0.80% of the stock is owned by company insiders.
Several institutional investors have recently bought and sold shares of the company. Wells Fargo & Company MN boosted its holdings in shares of BioScrip by 1.0% in the second quarter. Wells Fargo & Company MN now owns 114,810 shares of the company’s stock worth $312,000 after acquiring an additional 1,100 shares during the period. Schwab Charles Investment Management Inc. boosted its holdings in shares of BioScrip by 0.5% in the second quarter. Schwab Charles Investment Management Inc. now owns 490,698 shares of the company’s stock worth $1,333,000 after acquiring an additional 2,622 shares during the period. The Manufacturers Life Insurance Company boosted its stake in BioScrip by 9.8% during the second quarter. The Manufacturers Life Insurance Company now owns 99,569 shares of the company’s stock valued at $271,000 after buying an additional 8,914 shares during the period. Rhumbline Advisers boosted its stake in BioScrip by 9.2% during the second quarter. Rhumbline Advisers now owns 130,122 shares of the company’s stock valued at $353,000 after buying an additional 10,985 shares during the period. Finally, Voya Investment Management LLC boosted its stake in BioScrip by 41.4% during the second quarter. Voya Investment Management LLC now owns 50,799 shares of the company’s stock valued at $138,000 after buying an additional 14,867 shares during the period. 84.53% of the stock is owned by hedge funds and other institutional investors.
COPYRIGHT VIOLATION NOTICE: “BioScrip (BIOS) Cut to “Hold” at BidaskClub” was first reported by American Banking News and is the sole property of of American Banking News. If you are reading this story on another publication, it was copied illegally and reposted in violation of U.S. and international trademark and copyright law. The original version of this story can be read at https://www.americanbankingnews.com/2018/01/27/bioscrip-bios-cut-to-hold-at-bidaskclub.html.
BioScrip, Inc is engaged in providing infusion solutions. The Company partners with physicians, hospital systems, skilled nursing facilities, healthcare payors and pharmaceutical manufacturers to provide patients access to post-acute care services. The Company operates through Infusion Services segment.
Receive News & Ratings for BioScrip Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioScrip and related companies with MarketBeat.com's FREE daily email newsletter.